Integrated Quantitative Investments LLC Invests $948,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Integrated Quantitative Investments LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 33,102 shares of the specialty pharmaceutical company's stock, valued at approximately $948,000. Integrated Quantitative Investments LLC owned 0.10% of Collegium Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COLL. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter worth $40,000. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after acquiring an additional 483 shares in the last quarter. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after purchasing an additional 316 shares in the last quarter. Finally, Virtus Fund Advisers LLC acquired a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $72,000.

Remove Ads

Collegium Pharmaceutical Stock Down 0.8 %

Collegium Pharmaceutical stock traded down $0.21 during mid-day trading on Wednesday, reaching $25.20. The company's stock had a trading volume of 144,559 shares, compared to its average volume of 438,845. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 12 month low of $24.38 and a 12 month high of $42.29. The business's 50 day simple moving average is $29.60 and its 200 day simple moving average is $31.89. The company has a market capitalization of $809.73 million, a price-to-earnings ratio of 10.87 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company's stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now directly owns 164,269 shares of the company's stock, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of research reports. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of "Moderate Buy" and an average target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.